ORGANOGENESIS INC.

Company Overview

Organogenesis Holdings Inc. provides regenerative medicine products for advanced wound care, and the surgical and sports medicine markets. It entered the regenerative medicine market in 1998 with Apligraf. In 2017, it acquired NuTech Medical which gave it access to the amniotic category of the wound care market.

Its wound care products are Apligraf (for the treatment of VLUs and DFUs); Dermagraft (for the treatment of DFUs); and PuraPly AM (to address biofilm across a broad variety of wound types). Its amniotic product portfolio includes NuCel, NuShield, ReNu and Affinity. Affinity is the fresh amniotic membrane that undergoes a proprietary preservation method called AlloFresh enabling it to retain viable endogenous cells, growth factor/cytokine content, and native ECM structure. The company also provides TransCyte, a bioengineered tissue scaffold that promotes burn healing.

As of Dec. 31, 2024, the company had approximately 869 employees worldwide. Currently, substantially all of the company sales are in the U.S.

Financial Highlights (FY 2024)

Company's Business Segments

• Advanced Wound Care : Apligraf, Diabetic Foot Ulcers (DFUs), Dermagraft, PuraPly AM, VIA Matrix, Affinity, Novachor, Others
• Surgical & Sports Medicine : NuShield, PuraForce, Affinity, Novachor, PuraPly MZ, PuraPly AM, PuraPly SX, Others